Understanding the transcriptome to treat KRAS-driven tumors: how far can we get?

In lung cancer and in intestinal-tract tumors such as pancreatic cancer, colorectal cancer and cholangiocarcinoma, KRAS is the most widely mutated gene and an undisputable therapeutic target. Unfortunately, the vast majority of mutant KRAS-driven cancers remain refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative strategies to neutralize KRAS-mediated effects. In this se